Novavax Inc (NVAX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Vaccinessrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 37/100 (MEDIUM), 13.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 35.26% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
- Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
- Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
- Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
- Novavax (NVAX) Could Be 32% Above Fair Value On Medicare Policy Fears
- Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?
- Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
- Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Novavax Inc.
Full NVAX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.